No matching stocks found

Take a short break, or try a different search term.

Try widening your filters, clearing the search, or checking another sector.

“Good screens are built by narrowing the noise, not the signal.”

Plutux

Teladoc Health, Inc. (TDOC) stock news

Systems Boards Journals Stocks Insights Pricing Resources

SystemsBoardsJournalsStocksInsightsPricingResourcesMore

Teladoc Health, Inc.

$9.71

+0.62%

N/A+$0.06

Healthcare

Medical - Healthcare Information Services

NYSE

Active Trading

Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions ...

Recent News Overview Fundamental Analysis Key Metrics Price Action Financial Highlights Financial Statements Leadership Team CEO Profile Earnings Call Transcripts Employee Count Key Products Supply Chain Insider Transactions

Recent News of TDOC

Yahoo Finance7/9/2026Somewhat-Bullish (0.265)

Teladoc Health (TDOC) Stock May Be 40% Undervalued As Insurance Coverage Expands

Teladoc Health (TDOC) stock appears undervalued based on various valuation checks, with a Discounted Cash Flow (DCF) model suggesting a 39.9% discount to its intrinsic value. Despite a significant 93.9% stock decline over five years and a history of net losses, expanded insurance coverage and a Walmart partnership could drive future growth. The market currently applies a heavy discount to its sales on a Price/Sales basis, indicating potential for a valuation re-rating if the company can demonstrate sustainable profitability.

Teladoc Health (TDOC) Stock May Be 40% Undervalued As Insurance Coverage Expands

Simply Wall Street7/8/2026Neutral (0.006)

Does Teladoc (TDOC) Losing Russell Growth Index Spots Recast Its Long‑Term Growth Narrative?

Teladoc Health (TDOC) was removed from several Russell growth and small-cap indexes in late June 2026 due to flat near-term sales estimates and pressure on average revenue per user. This move highlights investor concerns about its growth trajectory, despite the company's efforts to stabilize revenue through partnerships like the one with Walmart. The article prompts investors to re-evaluate their belief in Teladoc's future growth potential amid these challenges.

Does Teladoc (TDOC) Losing Russell Growth Index Spots Recast Its Long‑Term Growth Narrative?

Fierce Healthcare7/8/2026Bullish (0.357)

Teladoc Health inks multi-year virtual care deal with National Basketball Players Association

Teladoc Health has signed a multi-year agreement with the National Basketball Players Association (NBPA) to become the union's preferred virtual primary care provider. This partnership grants current and retired NBA players and their families access to Teladoc’s comprehensive virtual care services, including urgent care, mental health, and preventive screenings. Both organizations emphasize the importance of flexible and accessible healthcare for individuals with demanding schedules.

Simply Wall Street7/8/2026Neutral (-0.131)

Does Teladoc (TDOC) Losing Russell Growth Index Spots Recast Its Long‑Term Growth Narrative?

Teladoc Health (TDOC) was recently removed from several Russell growth and small-cap indexes due to concerns about its growth trajectory, including flat near-term sales estimates and pressure on user revenue. This development intensifies scrutiny on Teladoc's efforts to stabilize revenue and margins, particularly through initiatives like its partnership with Walmart. The article prompts investors to re-evaluate Teladoc's future prospects in light of these index removals and differing analyst perspectives on its valuation.

TradingView7/7/2026Somewhat-Bearish (-0.341)

Teladoc Health, Inc. Stock 12‑Month Price Target Raised to $7.47, Implies 20% Downside

Teladoc Health, Inc.'s average price target has been increased to $7.47 from $7.40 based on estimates from 20 analysts, with a range of $5 to $10.50 per share. This updated target suggests a potential 20% downside from its July 6 closing price. The consensus rating for TDOC remains "Hold" among 26 analysts.

Teladoc Health (TDOC) Stock May Be 40% Undervalued As Insurance Coverage Expands

Yahoo Finance•7/9/2026

Teladoc Health (TDOC) Stock May Be 40% Undervalued As Insurance Coverage Expands

Teladoc Health (TDOC) stock appears undervalued based on various valuation checks, with a Discounted Cash Flow (DCF) model suggesting a 39.9% discount to its intrinsic value. Despite a significant 93.9% stock decline over five years and a history of net losses, expanded insurance coverage and a Walmart partnership could drive future growth. The market currently applies a heavy discount to its sales on a Price/Sales basis, indicating potential for a valuation re-rating if the company can demonstrate sustainable profitability.

Somewhat-Bullish (0.265)

financial markets

TDOC: Bullish (0.420)

Relevance 1.000

Does Teladoc (TDOC) Losing Russell Growth Index Spots Recast Its Long‑Term Growth Narrative?

Simply Wall Street•7/8/2026

Does Teladoc (TDOC) Losing Russell Growth Index Spots Recast Its Long‑Term Growth Narrative?

Teladoc Health (TDOC) was removed from several Russell growth and small-cap indexes in late June 2026 due to flat near-term sales estimates and pressure on average revenue per user. This move highlights investor concerns about its growth trajectory, despite the company's efforts to stabilize revenue through partnerships like the one with Walmart. The article prompts investors to re-evaluate their belief in Teladoc's future growth potential amid these challenges.

Neutral (0.006)

TDOC: Neutral (0.002)

Relevance 0.302

Fierce Healthcare•7/8/2026

Teladoc Health inks multi-year virtual care deal with National Basketball Players Association

Teladoc Health has signed a multi-year agreement with the National Basketball Players Association (NBPA) to become the union's preferred virtual primary care provider. This partnership grants current and retired NBA players and their families access to Teladoc’s comprehensive virtual care services, including urgent care, mental health, and preventive screenings. Both organizations emphasize the importance of flexible and accessible healthcare for individuals with demanding schedules.

Bullish (0.357)

TDOC: Bullish (0.455)

Relevance 1.000

Simply Wall Street•7/8/2026

Does Teladoc (TDOC) Losing Russell Growth Index Spots Recast Its Long‑Term Growth Narrative?

Teladoc Health (TDOC) was recently removed from several Russell growth and small-cap indexes due to concerns about its growth trajectory, including flat near-term sales estimates and pressure on user revenue. This development intensifies scrutiny on Teladoc's efforts to stabilize revenue and margins, particularly through initiatives like its partnership with Walmart. The article prompts investors to re-evaluate Teladoc's future prospects in light of these index removals and differing analyst perspectives on its valuation.

Neutral (-0.131)

TDOC: Somewhat-Bearish (-0.306)

Relevance 1.000

TradingView•7/7/2026

Teladoc Health, Inc. Stock 12‑Month Price Target Raised to $7.47, Implies 20% Downside

Teladoc Health, Inc.'s average price target has been increased to $7.47 from $7.40 based on estimates from 20 analysts, with a range of $5 to $10.50 per share. This updated target suggests a potential 20% downside from its July 6 closing price. The consensus rating for TDOC remains "Hold" among 26 analysts.

Somewhat-Bearish (-0.341)

financial markets

TDOC: Somewhat-Bearish (-0.341)

Relevance 1.000

Moomoo•7/7/2026

Teladoc Health Price Target Raised to $10.50/Share From $9.00 by B of A Securities

B of A Securities has increased its price target for Teladoc Health (TDOC) to $10.50 per share, up from the previous target of $9.00. This adjustment reflects a more positive outlook on the company's stock by the analyst firm.

Somewhat-Bullish (0.292)

financial markets

TDOC: Bullish (0.403)

Relevance 1.000

Moomoo•7/7/2026

BofA Securities Maintains Teladoc Health(TDOC.US) With Buy Rating, Raises Target Price to $10.5

BofA Securities has reiterated its Buy rating on Teladoc Health (TDOC.US) and increased the target price to $10.5. This adjustment reflects the firm's continued confidence in the telehealth provider's financial prospects and market position. The raised target price indicates an expectation of future stock appreciation for Teladoc Health.

Bullish (0.422)

financial markets

TDOC: Bullish (0.436)

Relevance 1.000

Insider Sell: Kelly Bliss Sells 2,500 Shares of Teladoc Health I

GuruFocus•7/7/2026

Insider Sell: Kelly Bliss Sells 2,500 Shares of Teladoc Health I

Kelly Bliss, President of U.S. Group Health at Teladoc Health Inc, sold 2,500 shares of the company on July 6, 2026. This transaction follows a pattern of 33 insider sells against 1 insider buy over the past year. Teladoc Health Inc is currently considered modestly overvalued based on its GF Value, with a price-to-GF-Value ratio of 1.13.

Somewhat-Bearish (-0.287)

financial markets

TDOC: Somewhat-Bearish (-0.288)

Relevance 1.000

Sahm•7/6/2026

Teladoc Health (TDOC) Faces Flat Sales, Is The Recent Rally Already Priced In?

Teladoc Health (TDOC) is facing scrutiny due to stagnant sales, declining average revenue per user, and flat near-term sales estimates, despite a recent rally in its stock price. While a "narrative fair value" suggests the stock is overvalued at $9.20 compared to a $7.40 estimate, another perspective based on its P/S ratio (0.7x) indicates it might be undervalued relative to industry peers. Investors are left to weigh if the recent stock surge has already accounted for its future growth potential amidst mixed signals.

Somewhat-Bearish (-0.231)

TDOC: Somewhat-Bearish (-0.248)

Relevance 1.000

Stock Titan•7/6/2026

Teladoc (TDOC) CAO sells shares after RSU vesting for tax withholding

Teladoc Health, Inc.'s Chief Accounting Officer, Joseph Ronald Catapano, reported a sale of 653 common shares at $9.10 each on July 2, 2026, to cover the tax withholding obligation from the vesting of 2,083 restricted stock units (RSUs) on July 1, 2026. These RSUs were part of a larger 25,000-unit grant from October 2024. After these transactions, Catapano holds 12,267 Teladoc common shares directly, with 10,418 RSUs remaining outstanding.

Neutral (-0.100)

TDOC: Neutral (-0.076)

Relevance 1.000

Investing.com•7/6/2026

Teladoc Health CAO sells $5,942 in common stock

Teladoc Health's Chief Accounting Officer, Joseph Ronald Catapano, sold 653 shares of company common stock for $5,942 to cover tax withholding obligations associated with RSU vestings. This transaction occurred on July 2, 2026, after 2,083 restricted stock units converted to common stock. Following the sale, Mr. Catapano directly holds 12,267 shares and 10,418 RSUs.

Somewhat-Bullish (0.206)

TDOC: Neutral (0.126)

Relevance 1.000

Stock Titan•7/6/2026

Teladoc (TDOC) executive Kelly Bliss sells 2,500 shares under 10b5-1 plan

Teladoc Health, Inc. executive Kelly Bliss, President of U.S. Group Health, sold 2,500 shares of Teladoc common stock at $9.50 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following this sale, Bliss directly holds 84,878 Teladoc shares.

Somewhat-Bearish (-0.296)

TDOC: Somewhat-Bearish (-0.273)

Relevance 1.000

Stock Titan•7/6/2026

TDOC (TDOC) Form 144: Director sales and proposed resale of 2,500 shares

Teladoc Health, Inc. (TDOC) has filed a Form 144 notice disclosing a proposed resale of 2,500 shares of common stock stemming from restricted stock vesting dated March 19, 2025. The filing also details three recent open-market sales by Kelly M. Bliss on June 2, June 29, and July 1, 2026, totaling 7,679, 2,500, and 2,500 shares respectively, with their associated proceeds. This Form 144 serves to provide public notice of these security transactions.

Neutral (0.033)

financial markets

TDOC: Neutral (0.026)

Relevance 1.000

Simply Wall Street•7/6/2026

Teladoc Health (TDOC) Faces Flat Sales, Is The Recent Rally Already Priced In?

Teladoc Health (TDOC) is experiencing stagnant sales and falling average revenue per user, yet its stock has seen a significant rally. While one valuation narrative suggests TDOC is overvalued at $9.20 against a $7.40 fair value, another perspective notes its P/S ratio of 0.7x is well below industry averages, raising questions about whether the recent price surge has already accounted for future growth or if the market has overreacted negatively.

Somewhat-Bearish (-0.268)

TDOC: Somewhat-Bearish (-0.270)

Relevance 1.000

Teladoc gives new BetterHelp product chief 50,000 shares

Stock Titan•7/3/2026

Teladoc gives new BetterHelp product chief 50,000 shares

Teladoc Health (NYSE: TDOC) has granted 50,000 restricted stock units to David Packles, the new Head of Product for BetterHelp, effective July 1, 2026. These RSUs will vest one-third after one year, with the remainder vesting quarterly over the subsequent two years. This inducement award, made under NYSE Rule 303A.08, aims to incentivize and retain key leadership as Teladoc continues to invest in its virtual care offerings.

Somewhat-Bullish (0.294)

TDOC: Somewhat-Bullish (0.254)

Relevance 0.995

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

GlobeNewswire•7/3/2026

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

Teladoc Health, Inc. announced an inducement award to David Packles, the new Head of Product for BetterHelp. This award, effective July 1, 2026, consists of 50,000 restricted stock units that will vest over three years based on continued service. The award was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan, adhering to NYSE Rule 303A.08.

Somewhat-Bullish (0.218)

TDOC: Somewhat-Bullish (0.221)

Relevance 1.000

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

Yahoo Finance UK•7/3/2026

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

Teladoc Health, Inc. announced an inducement award to David Packles, the new Head of Product for BetterHelp. This award consists of restricted stock units covering 50,000 shares of Teladoc Health's common stock, vesting over approximately three years based on continued service. The grant was approved by the Compensation Committee and issued under the company's 2023 Employment Inducement Incentive Award Plan as per NYSE Rule 303A.08.

Neutral (0.127)

TDOC: Neutral (0.123)

Relevance 1.000

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Teladoc (TDOC)

The Globe and Mail•7/3/2026

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Teladoc (TDOC)

Truist Financial analysts have maintained "Hold" ratings on both Incyte (INCY) and Teladoc (TDOC). For Incyte, analyst Srikripa Devarakonda cited a Moderate Buy consensus with a slight downside from its average price target, while Jailendra Singh maintained a Hold rating for Teladoc, also noting a projected downside from its average price target. These ratings suggest analysts are neither significantly bullish nor bearish on the short-term prospects of these healthcare stocks.

Neutral (0.020)

TDOC: Neutral (-0.094)

Relevance 1.000

Teladoc Health: A Rally Built on Shaky Foundations

Kavout | AI•7/3/2026

Teladoc Health: A Rally Built on Shaky Foundations

Teladoc Health's stock has surged, nearing 52-week highs, despite underlying financial woes like declining revenue in its BetterHelp segment and persistent unprofitability. The company faces significant challenges, including a heavy debt load and a negative revenue growth rate for FY2025. Wall Street analysts maintain a cautious "Hold" rating with a median price target significantly below the current trading price, suggesting the rally is built on speculative interest rather than fundamental strength.

Bearish (-0.649)

TDOC: Bearish (-0.624)

Relevance 1.000

Teladoc's Recovery Story Is Starting to Take Shape. Should You Buy the Stock?

Yahoo Finance•7/2/2026

Teladoc's Recovery Story Is Starting to Take Shape. Should You Buy the Stock?

Teladoc Health's stock is up 28% year-to-date, outperforming the S&P 500, despite a 2% revenue decline in Q1 and continued unprofitability. The market is reacting positively to developments like increased insurance coverage for BetterHelp and international expansion, alongside AI initiatives that improve efficiency. However, the company still faces challenges including a competitive virtual therapy market and potential complexities with global expansion, making its stock risky despite recent progress.

Neutral (0.124)

TDOC: Neutral (0.150)

Relevance 1.000

Insider Sell: Kelly Bliss Sells 2,500 Shares of Teladoc Health I

GuruFocus•7/2/2026

Insider Sell: Kelly Bliss Sells 2,500 Shares of Teladoc Health I

Kelly Bliss, President, U.S. Group Health at Teladoc Health Inc (TDOC), sold 2,500 shares on July 1, 2026, reducing her holdings to 87,378 shares. Over the past year, she has sold 48,608 shares with no purchases, contributing to a pattern of 1 insider buy and 31 insider sells at Teladoc. The stock was trading at $9, making it fairly valued with a price-to-GF-Value ratio of 1.07.

Somewhat-Bearish (-0.205)

TDOC: Somewhat-Bearish (-0.211)

Relevance 1.000

Stock Titan•7/1/2026

Teladoc Health (NYSE: TDOC) exec sells $22,500 under 10b5-1 plan

Teladoc Health executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock for $22,500 at $9.00 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, and leaves her with 87,378 shares. The sale is considered routine and does not necessarily reflect a change in insider sentiment regarding the stock.

Neutral (-0.068)

financial markets

TDOC: Neutral (-0.067)

Relevance 0.995

Stock Titan•7/1/2026

TDOC (NYSE) insider sale notices: 10,179 shares sold in June 2026

Teladoc Health, Inc. (TDOC) filed a Form 144, reporting sales of 10,179 shares in June 2026, totaling $79,817.73. The filing also detailed restricted stock vesting events in March and June 2025. These disclosures are routine for Form 144 filings and provide transparency on insider transactions.

Neutral (0.043)

financial markets

TDOC: Neutral (0.008)

Relevance 0.925

Teladoc Health president Kelly Bliss sells $21,250 in common stock By Investing.com

Investing.com Nigeria•7/1/2026

Teladoc Health president Kelly Bliss sells $21,250 in common stock By Investing.com

Kelly Bliss, President of U.S. Group Health at Teladoc Health, recently sold 2,500 shares of the company's common stock for a total of $21,250, following a 10b5-1 trading plan. The sale occurred after the stock experienced a 10% gain over the past week and a 21% return year-to-date. Teladoc Health also announced new partnerships with Walmart and developments for its BetterHelp platform, alongside updated price targets from analysts.

Neutral (0.131)

TDOC: Neutral (0.106)

Relevance 1.000

Stock Titan•6/30/2026

Teladoc Health (TDOC) executive sells 2,500 shares in 10b5-1 trade

Teladoc Health executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock at $8.50 per share on June 29, 2026, totaling $21,250. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following the sale, Bliss directly holds 89,878 shares of Teladoc Health common stock.

Somewhat-Bearish (-0.231)

TDOC: Somewhat-Bearish (-0.202)

Relevance 1.000

www.marketscreener.com•6/29/2026

Teladoc Health, Inc.(NYSE:TDOC) dropped from Russell Small Cap Comp Growth Benchmark

Teladoc Health, Inc. (NYSE:TDOC) has been removed from the Russell Small Cap Comp Growth Benchmark, along with the Russell 2500 Growth, Russell 2000 Growth, and Russell 3000E Growth Benchmarks. This news follows several recent updates for the company, including making its services available through Walmart's Better Care Services platform and reporting its Q1 2026 earnings. The company provides virtual healthcare services through its Integrated Care and BetterHelp segments.

Somewhat-Bearish (-0.346)

financial markets

TDOC: Somewhat-Bearish (-0.321)

Relevance 1.000

Teladoc Health (TDOC) Faces Broad Russell Index Exit Is Its Investment Narrative Being Rewritten?

Simply Wall Street•6/29/2026

Teladoc Health (TDOC) Faces Broad Russell Index Exit Is Its Investment Narrative Being Rewritten?

Teladoc Health (TDOC) has been removed from several Russell Growth indexes, including the Russell 2000, 2500, 3000, 3000E, and Small Cap Composite Growth indexes, which could lead to mechanical selling by index-linked funds. While this may increase share price volatility, the underlying investment narrative still hinges on the company's ability to deepen its role in virtual chronic disease and mental health management despite unprofitability. The real risk for investors involves persistent reimbursement and margin pressure, with current forecasts projecting $2.6 billion revenue and $173.1 million earnings by 2029, suggesting a 12% downside to its current price based on a $7.40 fair value.

Somewhat-Bearish (-0.236)

TDOC: Somewhat-Bearish (-0.235)

Relevance 1.000

Teladoc (TDOC) Moves 6.1% Higher: Will This Strength Last?

Yahoo Finance•6/29/2026

Teladoc (TDOC) Moves 6.1% Higher: Will This Strength Last?

Teladoc (TDOC) shares recently gained 6.1% due to increased trading volume and investor optimism regarding the company's growth prospects and turnaround strategy. While the company is focusing on expanding its virtual care platform and improving efficiency, its upcoming earnings report is projected to show a loss per share and a decrease in revenue. The stock currently holds a Zacks Rank #3 (Hold), and its future strength depends on trends in earnings estimate revisions.

Somewhat-Bullish (0.287)

TDOC: Somewhat-Bullish (0.278)

Relevance 1.000

www.marketscreener.com•6/29/2026

Teladoc Health, Inc.(NYSE:TDOC) dropped from Russell 2500 Growth Benchmark

Teladoc Health, Inc. (NYSE: TDOC) has been removed from the Russell 2500 Growth Benchmark. This news follows a series of similar removals from other Russell indices, including the Russell Small Cap Comp Growth, Russell 2000 Growth, and Russell 3000E Growth Benchmarks, all announced on June 29, 2026. The virtual healthcare provider's stock performance and underlying metrics likely led to these changes in its index inclusions.

Somewhat-Bearish (-0.283)

financial markets

TDOC: Somewhat-Bearish (-0.250)

Relevance 1.000

Stock Titan•6/29/2026

Affiliate files Form 144 to sell 2,500 restricted shares (TDOC)

An affiliate of Teladoc Health (TDOC) has filed a Form 144 to sell 2,500 restricted shares that vested on June 1, 2025. The filing also indicates that 7,679 shares were sold in the prior three months for over $58,000. Fidelity Brokerage Services LLC is listed as the broker for the proposed resale.

Neutral (0.027)

financial markets

TDOC: Neutral (0.038)

Relevance 0.926

Simply Wall Street•6/29/2026

Teladoc Health (TDOC) Faces Broad Russell Index Exit Is Its Investment Narrative Being Rewritten?

Teladoc Health (TDOC) was recently removed from several Russell Growth indexes, including the Russell 2000 and 3000, which could lead to mechanical selling by index-linked funds and impact its institutional ownership. While this exit adds share price volatility, it doesn't alter Teladoc's core investment narrative centered on virtual care adoption and partnerships like Walmart Better Care Services. Investors are advised to consider the long-term implications of reimbursement and margin pressures on its path to profitability, as analysts have varying forecasts for its revenue and earnings.

Somewhat-Bearish (-0.237)

TDOC: Somewhat-Bearish (-0.202)

Relevance 1.000

TradingView•6/27/2026

Enterprise value to revenue forward of Teladoc Health, Inc. – NYSE:TDOC

The article presents financial data for Teladoc Health, Inc. (NYSE: TDOC), specifically focusing on its enterprise value to revenue forward metric. It appears to be a financial data point provided by TradingView, indicating a quantitative measure for the company over a specific period.

Neutral (0.014)

financial markets

TDOC: Neutral (0.008)

Relevance 1.000

TradingView•6/27/2026

Price to sales forward of Teladoc Health, Inc. – NYSE:TDOC

This article provides financial information for Teladoc Health, Inc. (NYSE: TDOC), specifically focusing on its forward price-to-sales ratio. It details the company's ticker symbol on the New York Stock Exchange and touches upon various data sources and copyright information related to the financial data presented.

Neutral (0.011)

financial markets

TDOC: Neutral (0.021)

Relevance 1.000

TradingView•6/26/2026

Teladoc Health, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1 Sh

This page provides financial actuals and estimates for Teladoc Health, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1 Sh (BMFBOVESPA:T2DH34). Users can explore reported financial data and analyst estimates, comparing actual results with various estimates and visualizing trends over time across income statements, balance sheets, and cash flow statements. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.

Neutral (0.067)

TDOC: Neutral (0.052)

Relevance 1.000

Dr. Ethan Berke: Most Influential Clinical Executives 2026

Modern Healthcare•6/26/2026

Dr. Ethan Berke: Most Influential Clinical Executives 2026

Dr. Ethan Berke, the Chief Medical Officer of Teladoc Health, has been recognized as one of the "Most Influential Clinical Executives 2026" by Modern Healthcare. This recognition highlights his significant role and influence in the clinical executive field.

Bullish (0.804)

TDOC: Bullish (0.823)

Relevance 1.000

TradingView•6/26/2026

Teladoc Health, Inc. Actuals & Estimates (NYSE:TDOC)

This article provides financial actuals and estimates for Teladoc Health, Inc. (NYSE:TDOC), including its current stock price, volatility, market capitalization, and analyst forecasts. It details the company's past earnings and revenue performance, future earnings report date, and an overview of its financial statements. The article also touches upon technical analysis ratings for TDOC stock.

Neutral (0.107)

TDOC: Neutral (0.124)

Relevance 1.000

TradingView•6/26/2026

Teladoc Health, Inc. 실제 및 예상 (MUN:4LL)

This article provides an overview of Teladoc Health, Inc. (MUN:4LL) financial actuals and analyst estimates. It includes information on the company's stock ticker, future price forecasts, historical highs and lows, upcoming earnings reports, and key financial metrics such as earnings per share, revenue, net income, and EBITDA. The article also confirms that Teladoc Health, Inc. does not pay dividends and details its employee count.

Neutral (0.005)

TDOC: Neutral (0.025)

Relevance 1.000

Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note

Yahoo Finance UK•6/24/2026

Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note

Teladoc (TDOC) saw a 1.56% increase in its stock price, outperforming the S&P 500's loss, with a 16.69% rise over the past month. Despite a projected decrease in Q2 earnings per share and revenue, analysts' estimates for the company's annual performance show anticipated growth. Teladoc currently holds a Zacks Rank #3 (Hold).

Neutral (0.131)

TDOC: Neutral (0.101)

Relevance 1.000

Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note

Yahoo Finance Singapore•6/24/2026

Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note

Teladoc (TDOC) recently closed at $7.81, showing a 1.56% increase, outperforming the S&P 500's loss. Over the past month, TDOC stock climbed 16.69%, significantly exceeding the Medical sector's gain. Analysts anticipate Teladoc's upcoming earnings per share to be -$0.24, with revenue projected at $614.69 million for the quarter.

Somewhat-Bullish (0.317)

TDOC: Somewhat-Bullish (0.340)

Relevance 1.000

Form 13G Teladoc Health For: 22 June By Investing.com

Investing.com Canada•6/23/2026

Form 13G Teladoc Health For: 22 June By Investing.com

This article from Investing.com announces a Form 13G filing for Teladoc Health pertaining to June 22. It provides no further details beyond this announcement, merely stating the filing has occurred. The rest of the content includes market data and news headlines unrelated to the Form 13G.

Neutral (0.016)

financial markets

TDOC: Neutral (0.011)

Relevance 1.000

Stock Titan•6/23/2026

Voss entities and Travis Cocke report 9.03M shares in Teladoc (TDOC)

Voss entities and Travis Cocke have reported a beneficial ownership of 9.03 million shares in Teladoc Health (TDOC), representing approximately 5.0% of the company's outstanding shares. This disclosure, made via a SCHEDULE 13G SEC filing, details holdings across Voss Value Master Fund, Voss Value-Oriented Special Situations Fund, Voss Advisors GP, Voss Capital, and Travis W. Cocke directly. The reported holdings include 700,000 shares underlying currently exercisable call options and are based on 180,513,087 shares outstanding as of April 23, 2026.

Neutral (0.031)

TDOC: Neutral (0.045)

Relevance 1.000

MSN•6/19/2026

Teladoc Health extends rally to seventh straight session

Teladoc Health (TDOC) has extended its rally to a seventh consecutive session. The stock closed up 2.7% at $10.66 today, bringing its seven-day gain to 12% and its year-to-date performance to +28%. This positive movement follows a period of significant losses, as the stock had previously plummeted 79% in 2022 and 22% in 2023.

Bullish (0.434)

financial markets

TDOC: Bullish (0.441)

Relevance 1.000

Teladoc: Stagnant Growth Suggests Telehealth Still A Solution Waiting For A Problem (TDOC)

Seeking Alpha•6/19/2026

Teladoc: Stagnant Growth Suggests Telehealth Still A Solution Waiting For A Problem (TDOC)

Teladoc Health, Inc. (TDOC) has been upgraded from a "Sell" to a "Hold" rating due to slight strategic pivots aimed at new growth avenues, despite stagnant revenues. The company's Q1 2026 results showed a 2% year-over-year revenue decrease, though it remains EBITDA and cash flow positive. Key initiatives like a Walmart partnership and BetterHelp's insurance rollout are being watched as important tests for boosting utilization and top-line performance.

Neutral (0.047)

TDOC: Neutral (0.022)

Relevance 0.317

Teladoc Health Inc (TDOC) Earnings Forecast: Future EPS & Revenue Growth Estimates

TradingKey•6/18/2026

Teladoc Health Inc (TDOC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Teladoc Health Inc (TDOC) has an current earnings forecast score of 6.67, ranking 52 out of 76 in its industry, with an average price target of $8.50. Analysts largely recommend a "hold" for the stock, with 26 analysts contributing to the rating. The company's expected revenue for the next quarter is $614.91M, and its EPS for the previous quarter was -$0.14, with the next quarter's EPS projected at -$0.25.

Neutral (0.148)

TDOC: Neutral (0.103)

Relevance 1.000

Is Conflicting Earnings Signals And Brighter Estimates Altering The Investment Case For Teladoc Health (TDOC)?

Sahm•6/15/2026

Is Conflicting Earnings Signals And Brighter Estimates Altering The Investment Case For Teladoc Health (TDOC)?

Teladoc Health is facing conflicting signals, with analysts projecting a 26.32% year-over-year earnings decline for its upcoming report, yet recent estimate revisions suggest healthier near-term business conditions and improved profitability expectations. This combination suggests that while short-term earnings remain a risk, the focus for Teladoc's investment narrative is shifting towards evidence of margin progress and successful partnerships like the one with Walmart's Better Care Services platform. The stock's fair value is estimated at $7.12, indicating a 3% downside from its current price, though some analysts are far more optimistic about its long-term potential.

Somewhat-Bullish (0.178)

TDOC: Neutral (0.149)

Relevance 1.000

Simply Wall Street•6/14/2026

Is Conflicting Earnings Signals And Brighter Estimates Altering The Investment Case For Teladoc Health (TDOC)?

Teladoc Health (TDOC) is facing conflicting signals, with analysts projecting a 26.32% year-over-year earnings decline for its upcoming report, yet recent estimate revisions indicate healthier near-term business conditions and improving profitability expectations. The company's investment narrative relies on virtual care becoming core to patient management and Teladoc achieving sustainable profitability, with recent partnerships like the one with Walmart's Better Care Services platform aiming to expand consumer access and visit volumes. Despite these promising developments, investors should be aware of a less obvious risk concerning BetterHelp’s shift toward lower-margin insurance-based revenue.

Neutral (0.122)

TDOC: Neutral (-0.118)

Relevance 1.000

Simply Wall Street•6/14/2026

Is Conflicting Earnings Signals And Brighter Estimates Altering The Investment Case For Teladoc Health (TDOC)?

Analysts are projecting a 26.32% year-over-year earnings decline for Teladoc Health (TDOC) ahead of its upcoming report, yet recent estimate revisions suggest improving near-term business conditions. This conflicting outlook, coupled with strategic partnerships like the one with Walmart, highlights the importance of observing margin progress as a key catalyst. Despite an anticipated earnings decline, an analysis forecasts Teladoc reaching $2.6 billion in revenue and $164.1 million in earnings by 2029, suggesting a potential fair value of $7.12.

Neutral (0.040)

TDOC: Neutral (-0.068)

Relevance 1.000

Why Has Teladoc (TDOC) Stock Underperformed the Broader Market

Kavout•6/13/2026

Why Has Teladoc (TDOC) Stock Underperformed the Broader Market

Teladoc Health (TDOC) stock has significantly underperformed the broader market, trading near its 52-week low due to persistent revenue growth challenges and intense competition in the telehealth sector. Despite recent earnings beats, cautious forward guidance and concerns over declining user engagement are weighing on investor sentiment. The company's debt profile and ongoing goodwill impairment charges, stemming from past acquisitions, also contribute to investor apprehension.

Somewhat-Bearish (-0.167)

TDOC: Bearish (-0.433)

Relevance 1.000

Stock Titan•6/13/2026

Teladoc (NYSE: TDOC) CEO exercises stock units, sells shares for taxes

Teladoc Health, Inc. CEO Charles DiVita III exercised restricted and performance stock units, acquiring 42,802 common shares. He subsequently sold 18,074 shares at $6.942 each to cover tax withholding obligations related to the vesting of these awards. After these transactions, DiVita directly holds 414,622 shares of Teladoc common stock, indicating a routine compensation event rather than a discretionary sale for liquidity.

Neutral (0.035)

TDOC: Neutral (0.000)

Relevance 1.000

Teladoc stock surges 69% after Fair Value models spotted opportunity

Investing.com•6/13/2026

Teladoc stock surges 69% after Fair Value models spotted opportunity

Teladoc Health (NYSE:TDOC) stock surged 69% after InvestingPro's Fair Value analysis identified it as significantly undervalued in February 2026. The analysis, which calculates intrinsic value through multiple valuation methodologies, accurately predicted the stock's remarkable return from $4.68 to $7.34. The company's rally was driven by improved fundamentals and a new partnership with Walmart, and InvestingPro's current analysis suggests further upside potential.

Bullish (0.407)

TDOC: Bullish (0.484)

Relevance 1.000

About Us•Privacy Policy•Terms of Service•Join our Slack

© Plutux Technology Limited 2026